tbuckley/cabot-search huggingface dataset:
AMERICAN HEART ASSOCIATION, INC
Authors: Drs Andre, F Cournand, Dickinson Richards, New The
Journal: Circulation Research (1957)

The special Scientific Session for Physicians in General Medicine, on Friday, October 25, which precedes the Association's regular Scientific Sessions in Chicago, October 26-28, has been classified by the American Academy of General Practice as acceptable for Category II credit for Academy members.This all-day teaching program for general practitioners, under the Chairmanship of Howard B. Sprague, M.D., Boston, will include during the morning hours presentations on "Prevention and Management of Cardiovascular Emergencies" in pregnancy, in children, during anesthesia, after surgery, during drug therapy and in anxiety states.These will be followed by an afternoon discussion period and a panel on "Unsettled Questions in the Management of Cardiovascular Disease." Louis N.
Medicina, Buenos Aires
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Another Cephalosporin!
Authors: HAROLD C. NEU
Journal: Annals of Internal Medicine (1978)

Editorials1 November 1978Another Cephalosporin!HAROLD C. NEU, M.D.HAROLD C. NEU, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-89-5-719 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough readers of this journal undoubtedly know that the resistance of gram-negative bacteria to antibiotics is as much a problem today as staphylococcal resistance was in 1958, they are probably confused by the current plethora of cephalosporin-cefamycin agents. Have any of these new agents brought major improvements in antibacterial activity or pharmacokinetic properties? By the time this editorial is published, two new agents, cefamandole and cefoxitin, may be approved for use in the United States; these agents already are being used in Europe, as is another compound, cefuroxime, recently reviewed in a number of conference papers (1).It is unlikely...References1. International Conference on Cefuroxime. Proc R Soc Med 70(suppl 9):1-214, 1977 Google Scholar2. NEU H: Molecular modifications of antimicrobial agents to overcome drug resistance. Antibiot Chemother 20:87-111, 1976 CrossrefGoogle Scholar3. O'CALLAGHANSYKESGRIFFITHSTHORNTON CRAJ: Cefuroxime, a new cephalosporin antibiotic: activity in vitro. Antimicrob Agents Chemother 9:511-519, 1976 CrossrefMedlineGoogle Scholar4. NEUFU HK: Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and negative activity. Antimicrob Agents Chemother 13:657-664, 1978 CrossrefMedlineGoogle Scholar5. FOORD R: Cefuroxime: human pharmacokinetics. Antimicrob Agents Chemother 9:741-747, 1976 CrossrefMedlineGoogle Scholar6. BERGOGNE-BEREZINEVENBERTHELOTPIERRE EPGJ: Cefuroxime: pharmacokinetic study in bronchial secretions. Proc R Soc Med 70(suppl 9):34-37, 1977 MedlineGoogle Scholar7. BROGARDKOPFERSCHMITTPINGETARNAUDLAVILLAUREIX JJMJJ: Cefuroxime concentrations in serum, urine and bile: pharmacokinetic profile. Proc R Soc Med 70(suppl 9):42-49, 1977 MedlineGoogle Scholar8. NEU H: The role of β-lactamases in the resistance of gram-negative bacteria to penicillin and cephalosporin derivatives, in Infectious Disease Reviews, vol. 3, edited by HOLLOWAY WJ. Mount Kisco, New York, Futura Publishing Co., 1974, pp. 133-149 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Division of Infectious Diseases College of Physicians and Surgeons of Columbia University New York, New York PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAntimicrobial Agents in Pulmonary Infections 1 November 1978Volume 89, Issue 5_Part_1Page: 719-720KeywordsAntibioticsGram negative bacteriaPharmacokinetics Issue Published: 1 November 1978 PDF downloadLoading ...
ASSOCIATION NEWS.
Authors: William B. Atkinson
Journal: JAMA (1895)

<h3>The Baltimore Meeting.</h3> At a meeting of the Committee of Arrangements held February 26, the Committee of Transportation reported that the various railroads of the country had granted the customary reduction of rates to one fare and one-third on the certificate plan to the delegates attending the meeting, and their families. The Secretary of theAssociationwill publish detailed instructions for obtaining this reduction, through the columns of theJournal. Hotel rates to delegates will be given in the next issue of theJournal. The Hotel Stafford will be the headquarters of theAssociation. Among the entertainments determined upon will be an evening reception by the Trustees of the Johns Hopkins Hospital. A general entertainment will also be given by the profession of the city, but the details of this are not yet completed. Excursions at greatly reduced rates will be arranged to the Gettysburg battlefield, to Washington and to
Cancer incidence rate and mortality rate in sickle cell disease patients at Howard University Hospital: 1986–1995
Authors: Fitzroy W. Dawkins, Kyung Sook Kim, Richard S. Squires, Reginald Chisholm, John A. Kark, Elliott Perlin, Oswaldo Castro
Journal: American Journal of Hematology (1997)

The incidence of cancer in patients with sickle cell disease (SCD) is not known. The 10-year follow-up data on 696 patients with SCD was analyzed at our institution in order to determine the cancer incidence and cancer mortality rates. The age range was 18 to 79 years, with a mean age of 28.8 years. There were 377 females and 319 males. The median follow-up was 3 years. Five patients developed cancer during this period. The cancer incidence rate was 5/2,864 or 1.74 per 1,000 patient years. The 95% CI was 0.64 to 4.32 per 1,000 patient years. There were 68 deaths with 3 being due to cancer. The cancer mortality rate was 3/2,873 or 1.04 cases per 1,000 patient years. Our data represent the first published paper that the authors are aware of, where the cancer incidence and mortality rates have been calculated for any group of patients with SCD. Am. J. Hematol. 55:188–192, 1997. © 1997 Wiley-Liss, Inc.
A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy
Authors: R. M. Jotte, P. R. Conkling, C. Reynolds, A. R. Allen, J. W. Oliver
Journal: Journal of Clinical Oncology (2008)

8040 Background: SCLC accounts for about 13% of lung cancers and presents as extensive disease (ED-SCLC) in 60%-70% of patients (pts). Sensitive patients have an expected response rate to 2nd line therapy of 25%. Methods: This phase 2, open-label, multicenter trial compares second-line therapy with AMR vs topotecan in ED-SCLC pts (≥18 years, ECOG performance status ≤2), sensitive to first-line platinum-based therapy (recurrence or progression ≥90 days after first-line treatment). Pts were to be randomized 2:1 to AMR (40 mg/m2 5-min infusion daily x 3 days) or topotecan (1.5 mg/m2 30-min infusion daily x 5 days), both starting on Day 1 of a 21 day cycle. Treatment was continued until disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was response (RECIST). Progression free survival (PFS) and overall survival (OS) were also measured. 75 evaluable pts (50 randomized to AMR and 25 to topotecan;) were planned to be enrolled. Results: Enrollment to the study is closed with 76 patients. At the time of data cut-off, 57 pts were evaluable for response: 40 on AMR; 17 on topotecan. AMR was administered for a mean of 4.4 cycles (range: 1–14) and topotecan for a mean of 3 cycles (range: 1–8). To date, 16/40 AMR pts have had a response. Of these, 11 (2 CR, 9 PR) are confirmed and 5 (all PR) are pending follow-up assessments. Two topotecan pts have had a response (2 PR); one is confirmed and one is pending a follow-up assessment. PFS and OS data will be presented at the meeting. 67 pts were evaluable for safety. Hematological and gastrointestinal adverse events were the most commonly reported. Neutropenia, thrombocytopenia and leukopenia were seen at a rate 2-fold higher in the topotecan arm. No trends for classic anthracycline-induced cardiotoxicity have been observed. 3 AMR patients and 1 topotecan patient died due to neutropenic sepsis during cycles 1 or 2. This is consistent with death rates due to neutropenic sepsis reported in the literature for SCLC patients. Conclusions: AMR provides promising response rates and acceptable safety, versus topotecan, as second-line treatment in sensitive ED-SCLC patients. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Pharmion Corporation Genentech, Pharmion Corporation Pharmion Corporation Eli Lilly, Pharmion Corporation, sanofi-aventis Pharmion Corporation
Modulation and Functional Involvement of CB2 Peripheral Cannabinoid Receptors During B-Cell Differentiation
Authors: Pierre Carayon, Jean Marchand, Danielle Dussossoy, Jean-Marie Derocq, Omar Jbilo, Annie Bord, Monsif Bouaboula, Sylvaine Galiègue, Paul Mondière, Géraldine Pénarier, Gérard Le Fur, Thierry Defrance, Pierre Casellas
Journal: Blood (1998)
Where Have All the Students Gone?
Authors: Thomas D. Dublin
Journal: JAMA (1985)

Larger and larger numbers of US nationals are studying medicine abroad and they now comprise the foremost national group of foreign medical graduates (FMGs) seeking to enter the US health care system. The Educational Commission for Foreign Medical Graduates (ECFMG) is currently conducting a comprehensive study of 205,542 graduates of foreign medical schools who, during a 14-year study period, 1969 through 1982, have sought its certification, an established prerequisite for FMGs applying for training in an accredited hospital residency program and/or licensure within the United States. This report summarizes preliminary data on the 17,642 US citizens included in the study who attended 431 different medical schools in 79 foreign countries. Particular attention is given to their performance on the combined medical knowledge-English language competence examinations requisite to the awarding of ECFMG certification. (<i>JAMA</i>1985;253:376-381)
Section 42.—Gout
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Authors: S.L. Chan, R. Miksad, I. Cicin, Y. Chen, H.J. Klumpen, S. Kim, Z.Z. Lin, J. Youkstetter, S. Sen, A.-L. Cheng, A.B. El-Khoueiry, T. Meyer, R.K. Kelley, G.K. Abou-Alfa
Journal: Annals of Oncology (2019)
Transport to the Surgery
Authors: Geoffrey Hopcroft
Journal: BMJ (1971)

taste.(e) Sea-water drinking.(f) Craving for ice-a form of pica.8. (a) Buddenbrooks.(b) Dr. Faustus.(c) The Magic Mountain.(d) The Black Swan. 9. (a) A tick-borne protozoal infection which has been reported in splenectomized individuals.(b) Infectation with the gapeworm, which lives in respiratory tract of animals in the tropics.(c) Infestation with larval cyst of dog tapeworm.(d) Infection due to encephalitozoon causing disease in bees and silkworms, and rarely in man.(e) Common nematode infestation in cattle which may cause protein-losing enteropathy. 10. 1886. 1.
NERVOUS SYMPTOMS IN EX-SOLDIERS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DICHOTOMY, OR THE DIVISION OF FEES.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA Dermatology (2015)

Vitiligoa and Alopecia Areata in Graft-vs-Host Disease 23Allogeneic hematopoietic stem cell transplantation offers potential cure for certain hematologic diseases, but its use is limited by graft-vs-host disease (GvHD).Although cutaneous manifestations of chronic GvHD are highly variable and may resemble well-characterized autoimmune diseases, vitiligo and alopecia areata (AA) have not been well characterized in this setting.In this cross-sectional, retrospective study, Zuo et al demonstrate that, although vitiligo and AA were uncommon phenomena in this population, female donor and female donor to male recipient sex mismatch were significantly associated with the development of these conditions.
International Conference on Theories of Carclnogenesis: Facts, Fashion, or Fiction?
Journal: JNCI Journal of the National Cancer Institute (1986)

International Conference on Theories of Carclnogenesis: Facts, Fashion, or Fiction? Get access JNCI: Journal of the National Cancer Institute, Volume 76, Issue 3, March 1986, Page 555, https://doi.org/10.1093/jnci/76.3.555-e Published: 01 March 1986
Kawasaki disease termed "rising pediatric dilemma"
Authors: J. Kangilaski
Journal: JAMA (1981)

The number of cases of Kawasaki disease (or mucocutaneous lymph node disease) reported to the Centers for Disease Control (CDC), Atlanta, has doubled in the past year, causing one rheumatologist to term it "a rising pediatric dilemma." John J. Calabro, MD, director of rheumatology at St Vincent Hospital and professor of medicine and pediatrics at the University of Massachusetts Medical School, Worcester, is concerned not only about the growing incidence and the inability of physicians to pinpoint the cause of the disease. He is also concerned about the sequelae—a concern that is echoed by other physicians studying the disease. Calabro and Raquel V. Hicks, MD, associate professor of pediatrics and medicine at the University of Hawaii, Honolulu, both presented reports on Kawasaki disease at the recent Boston meeting of the American Rheumatism Association. They described their findings and the possibly grave implications: "In Japan, where the total number of cases
Intercomparison of Analytical Methods for Arsenic Speciation in Human Urine
Authors: Eric Crecelius, Janice Yager
Journal: Environmental Health Perspectives (1997)

An intercomparison exercise was conducted for the quantification of arsenic species in spiked human urine. The primary objective of the exercise was to determine the variance among laboratories in the analysis of arsenic species such as inorganic As (As+3 and As+5), monomethylarsonic acid (MMA), and dimethylarsinic acid (DMA). Laboratories that participated had previous experience with arsenic speciation analysis. The results of this interlaboratory comparison are encouraging. There is relatively good agreement on the concentrations of these arsenic species in urine at concentrations that are relevant to research on the metabolism of arsenic in humans and other mammals. Both the accuracy and precision are relatively poor for arsenic concentrations of less than about 5 micrograms/l.
Homocysteine and marginal vitamin deficiency. The importance of adequate vitamin intake
Authors: M. J. Stampfer
Journal: JAMA (1993)

Apart from calcium and iron requirements, nutrition in general (and vitamins in particular) has traditionally rated only a passing nod in medical school. Physicians in training are typically taught that a "balanced" diet is sufficient and that hardly anyone really needs vitamin supplements. Although frank vitamin deficiency is now uncommon in the United States, many investigators have long suspected that large segments of the US population are consuming suboptimal levels of several micronutrients; in recent years, compelling evidence has emerged that supports this contention. In national surveys, a substantial proportion of the US population consumes levels of several vitamins that are well below recommended intakes,<sup>1</sup>and recent evidence strongly indicates that such low intakes are associated with serious health consequences. The most striking recent example is the finding that folic acid supplements can reduce the risk of neural tube defects by approximately 70%. That relationship See also p 2693.
The Serum Treatment of Tuberculosis.
Authors: Kenneth W. Millican
Journal: JAMA (1898)

St. Louis, Mo., April 11, 1898. <h3>To the Editor:</h3> —In Dr. Waxham's letter on the above subject in your issue of April 9, Dr. Waxham asks, and the question is a fair one, why no criticism was made on the reports of the serum treatment in two papers in your issue of February 5, "in which sixteen cases were reported, of which fourteen were chronic cases, having existed from one to eleven years," and suggests that it may have been because those reports were more favorable. It has been the practice of Messrs. Jno. T. Milliken &amp; Co., on receiving first applications for serum, to caution the prospective users as to the limits within which claim is made for its usefulness. Dr. Waxham was himself so cautioned, for I find in my letter to him of Nov. 13, 1897, the following words: "Of course I need hardly say that its
Zomepirac sodium. A new nonaddicting analgesic
Authors: J. R. Lewis
Journal: JAMA (1981)

Zomepirac sodium (Zomax) is a new orally effective nonopioid analgesic that can relieve mild to severe pain. It is more effective than aspirin or codeine alone and is as effective as analgesic combinations containing codeine or other narcotics. Given orally, zomepirac has provided analgesia comparable with usual intramuscular doses of morphine in postoperative pain. With long-term use, neither tolerance to its analgesic effect nor psychic or physical dependence has been demonstrated. Like aspirin, zomepirac has anti-inflammatory and antipyretic actions and inhibits the synthesis of prostaglandins. Zomepirac is generally well tolerated with both short-term and long-term use; gastrointestinal reactions are the most frequently occurring side effects. (<i>JAMA</i>1981;246:377-379)
Medical Vampires
Authors: John F. Burnum
Journal: New England Journal of Medicine (1986)

The only two mammals to remove blood regularly from other mammals are vampire bats (subfamily, Desmodontinae) and humans. Vampires, dead people who rise from their graves at night to nourish themselves on the blood of the living (that is, Dracula and his ilk), are to be found only in movies and in Eastern European folklore. Werewolves, demonized people who, according to legend, take the form of wolves, are less fastidious about their source of nourishment; any part of the body will do. Vampire bats live exclusively on the blood of other animals. They obtain the blood painlessly by scooping out . . .